PATIENT REPORTED OUTCOMES IN THE DIAGNOSIS AND TREATMENT OF LYMPHOMA
Dr Elizabeth Goodall,
Haematologist and PhD student
Austin Health, Olivia Newton-John Cancer Research Institute & Monash Health, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne | February 2025
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
After completing her undergraduate degree in Medical Sciences at La Trobe University she went onto complete an Honours degree in malaria research before enrolling in Medicine at Monash University, Gippsland, Victoria in Australia.
Following medical school, she trained at Austin Health and successfully completed both clinical and laboratory haematology programs before moving to a lymphoma clinical trials fellowship at Monash Health. This fellowship provided essential clinical skills and has fostered a life-long interest in improving patient access to trials, finding ways to better select therapies for patients with blood cancers and learning more about the patient’s experience throughout treatment.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
This has led to her PhD on Patient Reported Outcomes (PROs) which will focus on the accurate documentation of the patient experience and learn how best to include this data for future clinical trial design, an essential component of obtaining excellent treatment outcomes. For this work she is the 2025 recipient of the Haematology Society of Australia and New Zealand and the Leukaemia Foundation New Investigator PhD Scholarship which will provide invaluable support throughout the PhD.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Professor Kim Hemsley
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Dr Dinesh Palipana
RESEARCH IN SPINAL CORD INJURY
@ GRIFFITH UNIVERSITY, QUEENSLAND, AUSTRALIA
